| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $38,643,751 | 20 | 100 |
| Shulman Joseph | Chief Technical Officer | 0 | $0 | 1 | $608,210 | $-608,210 |
| Garfield Alastair | Chief Scientific Officer | 0 | $0 | 1 | $912,703 | $-912,703 |
| German Christopher Paul | Corporate Controller & CAO | 0 | $0 | 2 | $930,921 | $-930,921 |
| Cramer Pamela J. | Chief Human Resources Officer | 0 | $0 | 4 | $2.99M | $-2.99M |
| TETRAULT LYNN A. | director | 0 | $0 | 1 | $3.71M | $-3.71M |
| Meeker David P | President and CEO | 0 | $0 | 1 | $5.13M | $-5.13M |
| Mazabraud Yann | EVP, Head of International | 0 | $0 | 1 | $6.62M | $-6.62M |
| Smith Hunter C | Chief Financial Officer | 0 | $0 | 8 | $8.84M | $-8.84M |
| Lee Jennifer Kayden | EVP, Head of North America | 0 | $0 | 1 | $8.9M | $-8.9M |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients …
Over the last 12 months, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $38.64M worth of Rhythm Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $20.66M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $201,713 was made by Meeker David P (President and CEO) on 2021‑03‑30.
| 2026-09-14 | Sale | Meeker David P | President and CEO | 50,000 0.0731% | $102.67 | $5.13M | -9.88% | |
| 2026-08-31 | Sale | Smith Hunter C | Chief Financial Officer | 62,774 0.0909% | $105.46 | $6.62M | -11.99% | |
| 2026-08-13 | Sale | Shulman Joseph | Chief Technical Officer | 5,079 0.0076% | $119.75 | $608,210 | -15.52% | |
| 2026-08-13 | Sale | Garfield Alastair | Chief Scientific Officer | 7,763 0.0115% | $117.57 | $912,703 | -15.52% | |
| 2026-08-13 | Sale | Lee Jennifer Kayden | EVP, Head of North America | 75,834 0.1119% | $117.38 | $8.9M | -15.52% | |
| 2026-08-12 | Sale | Mazabraud Yann | EVP, Head of International | 57,000 0.0821% | $116.15 | $6.62M | -16.56% | |
| 2026-06-22 | Sale | TETRAULT LYNN A. | director | 37,000 0.0534% | $100.32 | $3.71M | +3.22% | |
| 2026-05-15 | Sale | German Christopher Paul | Corporate Controller & CAO | 4,643 0.0069% | $92.21 | $428,131 | +9.66% | |
| 2026-03-04 | Sale | German Christopher Paul | Corporate Controller & CAO | 5,614 0.0083% | $89.56 | $502,790 | +2.18% | |
| 2026-02-19 | Sale | Smith Hunter C | Chief Financial Officer | 4,385 0.0066% | $101.26 | $444,004 | -9.84% | |
| 2026-02-17 | Sale | Smith Hunter C | Chief Financial Officer | 3,569 0.0053% | $101.38 | $361,810 | -9.26% | |
| 2026-02-12 | Sale | Smith Hunter C | Chief Financial Officer | 1,592 0.0024% | $98.23 | $156,380 | -2.94% | |
| 2026-02-11 | Sale | Smith Hunter C | Chief Financial Officer | 2,766 0.0042% | $98.61 | $272,766 | -5.14% | |
| 2026-02-10 | Sale | Smith Hunter C | Chief Financial Officer | 2,713 0.0041% | $103.00 | $279,429 | -9.18% | |
| 2026-02-05 | Sale | Smith Hunter C | Chief Financial Officer | 3,381 0.0052% | $106.06 | $358,599 | -9.96% | |
| 2026-02-04 | Sale | Smith Hunter C | Chief Financial Officer | 3,247 0.0048% | $105.99 | $344,145 | -13.33% | |
| 2025-12-11 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,350 0.0047% | $111.00 | $371,850 | -16.55% | |
| 2025-11-20 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,350 0.0052% | $105.00 | $351,750 | -1.72% | |
| 2025-11-10 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,515 0.0053% | $100.00 | $351,500 | +1.61% | |
| 2025-11-07 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 19,351 0.0253% | $98.82 | $1.91M | -1.15% |
| Meeker David P | President and CEO | 239258 0.3475% | $20.68M | 2 | 6 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| BARRETT M JAMES | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| MOTT DAVID M | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| KERINS PATRICK J | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| SANDELL SCOTT D | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| BASKETT FOREST | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| Viswanathan Ravi | 10 percent owner | 4909956 7.1312% | $424.42M | 1 | 0 | +9.57% |
| ORBIMED ADVISORS LLC | 10 percent owner | 2750079 3.9942% | $237.72M | 1 | 3 | +9.57% |
| MPM BIOVENTURES V, L.P. | 10 percent owner | 2696392 3.9162% | $233.08M | 1 | 0 | +9.57% |
| BAKER BROS. ADVISORS LP | 1878242 2.7279% | $162.36M | 1 | 0 | <0.0001% | |
| PFIZER INC | 10 percent owner | 1427639 2.0735% | $123.41M | 1 | 0 | +9.57% |
| Foley Todd | director | 909258 1.3206% | $78.6M | 1 | 44 | +9.57% |
| Ipsen, S.A. | 10 percent owner | 833099 1.21% | $72.01M | 1 | 0 | +9.57% |
| Flynn James E | 10 percent owner | 468505 0.6805% | $40.5M | 1 | 0 | +9.57% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 164 | +56.36% | 8M | +11.7% |
| Decreased Positions | 132 | -45.36% | 6M | -8.63% |
| New Positions | 57 | New | 1M | New |
| Sold Out Positions | 42 | Sold Out | 2M | Sold Out |
| Total Postitions | 323 | +11% | 73M | +3.06% |
| Blackrock, Inc. | $661,796.00 | 9.41% | 6.3M | +34,677 | +0.55% | 2025-09-30 |
| Ra Capital Management, L.P. | $596,600.00 | 8.48% | 5.68M | +120,000 | +2.16% | 2025-09-30 |
| Baker Bros. Advisors Lp | $588,527.00 | 8.37% | 5.6M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $524,675.00 | 7.46% | 5M | +1M | +39.21% | 2025-09-30 |
| Primecap Management Co/Ca/ | $447,643.00 | 6.36% | 4.26M | -615,178 | -12.61% | 2025-09-30 |
| Nea Management Company, Llc | $305,574.00 | 4.34% | 2.91M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $256,116.00 | 3.64% | 2.44M | +20,670 | +0.85% | 2025-09-30 |
| Fmr Llc | $225,266.00 | 3.2% | 2.15M | +191,742 | +9.82% | 2025-09-30 |
| State Street Corp | $213,029.00 | 3.03% | 2.03M | +121,050 | +6.35% | 2025-09-30 |
| Goldman Sachs Group Inc | $198,854.00 | 2.83% | 1.89M | +159,941 | +9.22% | 2025-09-30 |